GPT and Thrombocytopenia: Of the patients who received TMZ in the concurrent phase, 1.5% (n = 6) developed leucopenia below the predefined threshold level of 1.5 × 109/L corresponding to a grade 3 toxicity or higher, 8.3% (n = 33) developed thrombocytopenia below the predefined threshold level of 100 × 109/L corresponding to a grade 2 toxicity or higher, and 2.3% (n = 9) elevated ALT, AST or bilirubin levels above the predefined levels corresponding to a grade 2 toxicity or higher, that required discontinuation of TMZ.